Ocular complications of AIDS, particularly cytomegalovirus (CMV) retinitis are associated with poor visual outcomes, impaired quality of life, and high treatment costs. Secular trends in HIV disease management, such as the use of highly active anti-retroviral therapy, are altering the epidemiology of these ocular complications, but have not eliminated them. Accordingly, the primary goals of the Studies of Ocular Complications of AIDS (SOCA) Research Group, organized in response to a request for application from the National Eye Institute, are: 1) to evaluate strategies for the treatment of and, when indicated, the prevention of CMV retinitis via randomized, controlled clinical trials; and 2) to investigate the changing epidemiology of the ocular complications of AIDS, in particular, to identify subpopulations at high risk for CMV retinitis and other ocular complications. A related goal of the SOCA Research Group is to investigate the pathogenesis of CMV retinitis, including the relationship between HIV and CMV. Current and proposed studies inside: 1) the ongoing Ganciclovir-Cidofovir Cytomegalovirus Retinitis Trial, a randomized controlled clinical trial comparing cidofovir to a regiment of the ganciclovir implant and oral ganciclovir for the treatment of CMV retinitis; and 2) a longitudinal observational study of the ocular complications of AIDS to assess the impact of secular trends in AIDS management on the incidence and clinical course of these ocular complications over time. Outcomes of interest include visual acuity, visual field, photographic assessments, quality of life, cost effectiveness, and virologic outcomes such as CMV viral load and HIV viral load. This application is for the Chairman's Office of the Studies of Ocular Complications of AIDS.

National Institute of Health (NIH)
National Eye Institute (NEI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Special Emphasis Panel (ZEY1-VSN (04))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Johns Hopkins University
Schools of Medicine
United States
Zip Code
Grover, Surbhi; Desir, Fidel; Jing, Yuezhou et al. (2018) Reduced Cancer Survival Among Adults With HIV and AIDS-Defining Illnesses Despite No Difference in Cancer Stage at Diagnosis. J Acquir Immune Defic Syndr 79:421-429
Yanik, Elizabeth L; Hernández-Ramírez, Raúl U; Qin, Li et al. (2018) Brief Report: Cutaneous Melanoma Risk Among People With HIV in the United States and Canada. J Acquir Immune Defic Syndr 78:499-504
Jabs, A W; Jabs, D A; Van Natta, M L et al. (2018) Insurance status and mortality among patients with AIDS. HIV Med 19:7-17
Altekruse, Sean F; Shiels, Meredith S; Modur, Sharada P et al. (2018) Cancer burden attributable to cigarette smoking among HIV-infected people in North America. AIDS 32:513-521
AIDS-defining Cancer Project Working Group of IeDEA, COHERE in EuroCoord (2018) Non-Hodgkin lymphoma risk in adults living with HIV across five continents. AIDS 32:2777-2786
Elion, Richard A; Althoff, Keri N; Zhang, Jinbing et al. (2018) Recent Abacavir Use Increases Risk of Type 1 and Type 2 Myocardial Infarctions Among Adults With HIV. J Acquir Immune Defic Syndr 78:62-72
Anderegg, Nanina; Johnson, Leigh F; Zaniewski, Elizabeth et al. (2017) All-cause mortality in HIV-positive adults starting combination antiretroviral therapy: correcting for loss to follow-up. AIDS 31 Suppl 1:S31-S40
Drozd, Daniel R; Kitahata, Mari M; Althoff, Keri N et al. (2017) Increased Risk of Myocardial Infarction in HIV-Infected Individuals in North America Compared With the General Population. J Acquir Immune Defic Syndr 75:568-576
Jabs, Douglas A; Van Natta, Mark L; Holland, Gary N et al. (2017) Cytomegalovirus Retinitis in Patients With Acquired Immunodeficiency Syndrome After Initiating Antiretroviral Therapy. Am J Ophthalmol 174:23-32
Dubrow, Robert; Qin, Li; Lin, Haiqun et al. (2017) Association of CD4+ T-cell Count, HIV-1 RNA Viral Load, and Antiretroviral Therapy With Kaposi Sarcoma Risk Among HIV-infected Persons in the United States and Canada. J Acquir Immune Defic Syndr 75:382-390

Showing the most recent 10 out of 116 publications